Related Experiment Video

Updated: Mar 3, 2026

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.3K

Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations

R Taneja1, A J Garcia-Prats2, J Furin2

  • 1The Global Alliance for TB Drug Development, New York, New York, USA.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|November 14, 2015
PubMed

Insights

Developing child-friendly dispersible tablets for multidrug-resistant tuberculosis (TB) is crucial. These formulations improve drug accessibility and adherence in children, combating treatment failure and the spread of resistant TB.

Area of Science:

  • Paediatric pharmacology
  • Infectious diseases
  • Pharmaceutical development

Background:

  • Increasing global access to second-line anti-tuberculosis (TB) drugs for multidrug-resistant TB in children.
  • Lack of child-friendly drug formulations, particularly dispersible tablets, for paediatric TB treatment.
  • Dispersible tablets offer advantages in stability, shelf-life, cost, and adherence for paediatric TB management.

Purpose of the Study:

  • To highlight the need for child-friendly second-line anti-TB drug formulations.
  • To discuss challenges in developing dispersible tablet formulations for paediatric use.
  • To propose strategies for overcoming development obstacles and advocating for paediatric considerations in new drug development.

Main Methods:

  • Literature review and discussion of current challenges in paediatric TB drug formulation.
  • Analysis of the advantages of dispersible tablets for paediatric anti-TB treatment.
  • Exploration of strategies to facilitate the development of child-friendly TB medications.

Main Results:

  • No second-line anti-TB drugs are currently available in dispersible formulations for children.
  • Significant obstacles exist in developing these essential paediatric formulations.
  • Dispersible tablets offer a viable solution for improving drug stability, affordability, and adherence in paediatric TB treatment.

Conclusions:

  • There is an urgent need for the development of child-friendly dispersible tablets for second-line anti-TB drugs.
  • Addressing formulation challenges and advocating for early paediatric consideration in drug development are critical.
  • Improved formulations will enhance treatment adherence, reduce treatment failure, and mitigate the spread of drug-resistant TB in children.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format12:39

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Published on: June 24, 2011

38.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
411
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
388
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
457
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
340
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
694